Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research

Advances in Anatomic Pathology

Volumn 24, Issue 5, 2017, Pages 235-251

  Hendry, Shona ^a,c   Salgado, Roberto ^a,an   Gevaert, Thomas ^aj,al   Russell, Prudence A ^d,f   John, Tom ^g,h,i   Thapa, Bibhusal ^d,h   Christie, Michael ^e   Van De Vijver, Koen ^p   Estrada, M V ^cb   Gonzalez Ericsson, Paula I ^bg   Sanders, Melinda ^a   Solomon, Benjamin ^b   Solinas, Cinzia ^am   Van Den Eynden, Gert G G M ^ai,am   Allory, Yves ^q,r,s   Preusser, Matthias ^y   Hainfellner, Johannes ^z   Pruneri, Giancarlo ^ab,ac   Vingiani, Andrea ^ab,ac   Demaria, Sandra ^by   Symmans, Fraser ^bz   Nuciforo, Paolo ^ag   Comerma, Laura ^ag   Thompson, E A ^br   Lakhani, Sunil ^j,k   Kim, Seong Rim ^bf   Schnitt, Stuart ^bm,bn   Colpaert, Cecile ^a   Sotiriou, Christos ^an   Scherer, Stefan J ^cf   Ignatiadis, Michail ^an   Badve, Sunil ^bs   Pierce, Robert H ^bt   Viale, Giuseppe ^ad   Sirtaine, Nicolas ^an   Penault Llorca, Frederique ^w,x   Sugie, Tomohagu ^ap   Fineberg, Susan ^bj,bk   Paik, Soonmyung ^aq,bf   Srinivasan, Ashok ^bf   Richardson, Andrea ^a,bl,bn   Wang, Yihong ^bd,be   Chmielik, Ewa ^ar,as   Brock, Jane ^bl,bn   Johnson, Douglas B ^bg,bh   Balko, Justin ^bg,bh   Wienert, Stephan ^au,av   Bossuyt, Veerle ^bi   Michiels, Stefan ^t   Ternes, Nils ^t   Burchardi, Nicole ^aw   Luen, Stephen J ^b,c   Savas, Peter ^b,c   Klauschen, Frederick ^au   Watson, Peter H ^ax,az   Nelson, Brad H ^a,ax,ay   Criscitiello, Carmen ^ab   O'Toole, Sandra ^l,m   Larsimont, Denis ^an   De Wind, Roland ^an   Curigliano, Giuseppe ^ab   André, Fabrice ^u,v   Lacroix Triki, Magali ^u   Van De Vijver, Mark ^p   Rojo, Federico ^ah   Floris, Giuseppe ^ak   Bedri, Shahinaz ^bc   Sparano, Joseph ^bj   Rimm, David ^bi   Nielsen, Torsten ^ba   Kos, Zuzana ^bb   Hewitt, Stephen ^cd   Singh, Baljit ^bu   Farshid, Gelareh ^n,o   Loibl, Sibylle ^aw   Allison, Kimberly H ^ca   Tung, Nadine ^bo   Adams, Sylvia ^bu,bv   Willard Gallo, Karen ^am   Horlings, Hugo M ^a   Gandhi, Leena ^bp,bu   Moreira, Andre ^bw   Hirsch, Fred ^bq   Dieci, Maria V ^ae,af   Urbanowicz, Maria ^ao   Brcic, Iva ^aa   Korski, Konstanty ^at   Gaire, Fabien ^at   Koeppen, Hartmut ^cc   Lo, Amy ^ca,cc   Giltnane, Jennifer ^cc   Rebelatto, Marlon C ^ce   Steele, Keith E ^ce   Zha, Jiping ^ce   Emancipator, Kenneth ^a,cg   Juco, Jonathan W ^cg   Denkert, Carsten ^au   Reis Filho, Jorge ^bx   Loi, Sherene ^b   Fox, Stephen B ^a,c   more..

^a Department of Pathology ^*  (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c Molecular Imaging and Therapeutic Nuclear Medicine at Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology at University of Melbourne   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g AUSTIN HEALTH   (Australia)

^h OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

ⁱ LA TROBE UNIVERSITY   (Australia)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^l GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^m Department of Microbiology   (Australia)

ⁿ SA Pathology   (Australia)

^o UNIVERSITY OF ADELAIDE   (Australia)

^p NETHERLANDS CANCER INSTITUTE   (Netherlands)

^q UNIVERSITÉ PARIS EST   (France)

^r INSERM   (France)

^s HENRI MONDOR HOSPITAL   (France)

^t CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^u Universite Paris Sud   (France)

^v UNIVERSITÉ PARIS SACLAY   (France)

^w Jean Perrin Comprehensive Cancer Centre   (France)

^x UNIVERSITÉ CLERMONT AUVERGNE   (France)

^y Division of Clinical Oncology Department of Medicine   (Austria)

^z MEDICAL UNIVERSITY OF VIENNA   (Austria)

^aa MEDICAL UNIVERSITY OF GRAZ   (Austria)

^ab EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ac University School of Medicine   (Italy)

^ad UNIVERSITY OF MILAN   (Italy)

^ae UNIVERSITY OF PADOVA   (Italy)

^af VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^ag VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^ah UAM)   (Spain)

^ai Department of Anesthesiology and Pain Management   (Belgium)

^aj SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^ak UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^al Algemeen Ziekenhuis Klina   (Belgium)

^am Molecular Immunology Unit   (Belgium)

^an JULES BORDET INSTITUTE   (Belgium)

^ao EORTC DATA CENTER   (Belgium)

^ap KANSAI MEDICAL UNIVERSITY   (Japan)

^aq Yonsei University College of Medicine   (South Korea)

^ar INSTITUTE OF ONCOLOGY   (Poland)

^as INSTITUTE OF ONCOLOGY   (Poland)

^at ROCHE DIAGNOSTICS GMBH   (Germany)

^au CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^av VMSCOPE GMBH   (Germany)

^aw German Breast Group   (Germany)

^ax BRITISH COLUMBIA CANCER AGENCY   (Canada)

^ay UNIVERSITY OF VICTORIA   (Canada)

^az Laboratory Medicine   (Canada)

^ba UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^bb UNIVERSITY OF OTTAWA   (Canada)

^bc WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^bd RHODE ISLAND HOSPITAL   (United States)

^be BROWN UNIVERSITY   (United States)

^bf NSABP Foundation Inc   (United States)

^bg VANDERBILT INGRAM CANCER CENTER   (United States)

^bh VANDERBILT UNIVERSITY   (United States)

^bi YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bj ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^bk MONTEFIORE MEDICAL CENTER   (United States)

^bl BRIGHAM AND WOMEN S HOSPITAL   (United States)

^bm Beth Israel Deaconess Cancer Center   (United States)

^bn HARVARD MEDICAL SCHOOL   (United States)

^bo BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^bp DANA FARBER CANCER INSTITUTE   (United States)

^bq UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^br MAYO CLINIC   (United States)

^bs INDIANA UNIVERSITY   (United States)

^bt Fred Hutchinson Cancer Research Center   (United States)

^bu NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^bv NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bw NEW YORK UNIVERSITY   (United States)

^bx MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^by WEILL CORNELL MEDICAL COLLEGE   (United States)

^bz UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ca STANFORD UNIVERSITY   (United States)

^cb UNIVERSITY OF CALIFORNIA   (United States)

^cc GENENTECH INC   (United States)

^cd NATIONAL CANCER INSTITUTE   (United States)

^ce Translational Sciences   (United States)

^cf NOVARTIS PHARMA AG   (Switzerland)

^cg MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

biomarkers; cancer; immunotherapy; lymphocytes; pathology; tumor infiltrating

Indexed keywords

BREAST CARCINOMA; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTRADUCTAL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; NEOADJUVANT CHEMOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SOLID MALIGNANT NEOPLASM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; BREAST TUMOR; PATHOLOGIST; PATHOLOGY; SECOND CANCER;

TUMOR MARKER;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS, SECOND PRIMARY; PATHOLOGISTS;

EID: 85027413331     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000162     Document Type: Review

References (127)

1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014-1022.
2. Coulie PG, Van den Eynde BJ, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14:135-146.
3. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306.
4. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232:199-209.
5. Donnem T, Kilvaer TK, Andersen S, et al. Strategies for clinical implementation of TNM-immunoscore in resected nonsmall-cell lung cancer. Ann Oncol. 2016;27:225-232.
6. Masucci GV, Cesano A, Hawtin R, et al. Validation of biomarkers to predict response to immunotherapy in cancer: volume I-pre-analytical and analytical validation. J Immunother Cancer. 2016;4:76.
7. Dobbin KK, Cesano A, Alvarez J, et al. Validation of biomarkers to predict response to immunotherapy in cancer: volume II-clinical validation and regulatory considerations. J Immunother Cancer. 2016;4:77.
8. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446-1452.
9. Altman DG, McShane LM, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.
10. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387-391.
11. Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12:584-596.
12. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's role in cancer suppression and promotion. Science. 2011;331:1565-1570.
13. Dieu-Nosjean MC, Goc J, Giraldo NA, et al. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35:571-580.
14. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-271.
15. Schatton T, Scolyer RA, Thompson JF, et al. Tumorinfiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2014;1102:287-324.
16. Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41: 2645-2654.
17. Vayrynen JP, Vornanen JO, Sajanti S, et al. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. Virchows Arch. 2012;460:455-465.
18. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666.
19. Stack EC, Wang C, Roman KA, et al. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2014;70:46-58.
20. Stack EC, Foukas PG, Lee PP. Multiplexed tissue biomarker imaging. J Immunother Cancer. 2016;4:9.
21. Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, et al. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Lab Invest. 2015;95:385-396.
22. Cesano A, Beecham J, Webster P, et al. Spatially-resolved, multiplexed digital characterization of protein distribution and abundance in FFPE tissue sections (abstract). Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. 2016;76: Abstract no. 1371.
23. Longuespee R, Fleron M, Pottier C, et al. Tissue proteomics for the next decade? Towards a molecular dimension in histology. OMICS. 2014;18:539-552.
24. Balluff B, Schone C, Hofler H, et al. MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. Histochem Cell Biol. 2011;136:227-244.
25. Young YK, Bolt AM, Ahn R, et al. Analyzing the tumor microenvironment by flow cytometry. Methods Mol Biol. 2016;1458:95-110.
26. Buisseret L, Garaud S, de Wind A, et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer. Oncoimmunology. 2017;6:e1257452.
27. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938-945.
28. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
29. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
30. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl JMed. 2015;372:320-330.
31. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909-1920.
32. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311-319.
33. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
34. Brahmer JR, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
35. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
36. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-1813.
37. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956-965.
38. Topalian SL, Taube JM, Anders RA, et al. Mechanismdriven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275-287.
39. Garber K. Predictive biomarkers for checkpoints, first tests approved. Nat Biotechnol. 2015;33:1217-1218.
40. Kerr KM, Hirsch FR. Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? Arch Pathol Lab Med. 2016;140:326-331.
41. Tang H, Wang Y, Chlewicki LK, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;29:285-296.
42. Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61:1019-1031.
43. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567.
44. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-smallcell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-1846.
45. Pruneri G, Lazzeroni M, Bagnardi V, et al. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017;28:321-328.
46. Leung SCY, Nielsen TO, Zabaglo L, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2:16014.
47. Moore OS, Foote FW. The relatively favorable prognosis of medullary carcinoma of the breast. Cancer. 1949;2: 635-640.
48. Richardson WW. Medullary carcinoma of the breast: a distinctive tumour type with a relatively good prognosis following mastectomy. Br J Cancer. 1956;10:415-423.
49. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40:1365-1385.
50. Bloom HJG, Richardson WW, Field JR. Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1, 411 cases of breast cancer followed for 20 years. BMJ. 1970;3:181-188.
51. Rapin V, Contesso G, Mouriesse H, et al. Medullary breast carcinoma: a reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer. 1988;61:2503-2510.
52. Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2:1354-1360.
53. Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228-241.
54. Mao Y, Qu Q, Chen X, et al. The prognostic value of tumorinfiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. PLoS One. 2016;11:e0152500.
55. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, et al. The prognostic and predicting roles of tumor-infiltrating lymphocytes in breast cancer: a meta-analysis. Open Breast Cancer J. 2014;6:9-19.
56. Yu X, Zhang Z, Wang Z, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2016; 18:497-506.
57. Loi S, Drubay D, Adams S, et al. Abstract S1-03: pooled individual patient data analysis of tumor infiltrating lymphocytes (TILs) in primary triple negative breast cancer (TNBC) treated with anthracycline-based chemotherapy. Cancer Res. 2016;76:S1-03.
58. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, et al. The prognostic value of tumor-infiltrating lymphocytes in triplenegative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148:467-476.
59. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860-867.
60. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25:1544-1550.
61. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105-113.
62. Denkert C, Von Minckwitz G, Brase JC, et al. Tumorinfiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983-991.
63. Issa-Nummer Y, Darb-Esfahani S, Loibl S, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the Neoadjuvant GeparQuinto Trial. PLoS One. 2013;8:e79775.
64. West NR, Milne K, Truong PT, et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13:R126.
65. Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12, 439 patients. Ann Oncol. 2014;25:1536-1543.
66. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-2966.
67. Shou J, Zhang Z, Lai Y, et al. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis. BMC Cancer. 2016; 16:687.
68. Jiang D, Gao Z, Cai Z, et al. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer. 2015;15:727.
69. West NR, Kost SE, Martin SD, et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptornegative breast cancer. Br J Cancer. 2013;108:155-162.
70. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol. 2008;21: 1527-1532.
71. Liu S, Foulkes WD, Leung SCY, et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16:432.
72. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24:5373-5380.
73. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54-61.
74. Mattarollo SR, Loi S, Duret H, et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 2011;71:4809-4820.
75. Generali D, Bates G, Berruti A, et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009;15:1046-1051.
76. Mao Y, Qu Q, Zhang Y, et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and metaanalysis. PLoS One. 2014;9:e115103.
77. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Abstract S1-09: evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy- a metaanalysis of 3771 patients. Cancer Res. 2017;77:S1-09.
78. Vinayak S, Gray RJ, Adams S, et al. Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. J Clin Oncol. 2014;32:1000.
79. Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611-618.
80. Garcia-Martinez E, Gil GL, Benito AC, et al. Tumorinfiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16:488.
81. Workel HH, Komdeur FL, Wouters MC, et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur J Cancer. 2016;60:1-11.
82. Wang ZQ, Milne K, Derocher H, et al. CD103 and intratumoral immune response in breast cancer. Clin Cancer Res. 2016;22:6290-6297.
83. Mani NL, Schalper KA, Hatzis C, et al. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Res. 2016;18:78.
84. Nawaz S, Heindl A, Koelble K, et al. Beyond immune density: critical role of spatial heterogeneity in estrogen receptornegative breast cancer. Mod Pathol. 2015;28:766-777.
85. Buisseret L, Desmedt C, Garaud S, et al. Reliability of tumor infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod Pathol. 2017. [Epub ahead of print]. doi: 10.1038/modpathol.2017.43.
86. Pang JM, Gorringe KL, Fox SB. Ductal carcinoma in situ- update on risk assessment and management. Histopathology. 2016;68:96-109.
87. Van Bockstal M, Libbrecht L, Floris G, et al. The Baader- Meinhof phenomenon in ductal carcinoma in situ of the breast. Histopathology. 2016;69:522-523.
88. Thompson E, Taube JM, Elwood H, et al. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016;29:249-258.
89. Campbell MJ, Baehner F, O'Meara T, et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017;161:17-28.
90. Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006;59:972-977.
91. Lal A, Chan L, Devries S, et al. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat. 2013;139:381-390.
92. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-5434.
93. Cimino-Mathews A, Ye X, Meeker A, et al. Metastatic triplenegative breast cancers at first relapse have fewer tumorinfiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013;44:2055-2063.
94. Ogiya R, Niikura N, Kumaki N, et al. Comparison of tumorinfiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 2016;107: 1730-1735.
95. Sobottka B, Pestalozzi B, Fink D, et al. Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology. 2016;5:e1153208.
96. Baine MK, Turcu G, Zito CR, et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget. 2015;6:24990-25002.
97. Mansfield AS, Aubry MC, Moser JC, et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016;27:1953-1958.
98. Ben-Avi R, TItzhaki O, SimanskyD, et al.Metastatic lung lesions as a preferred resection site for immunotherapy with tumor infiltrating lymphocytes. J Immunother. 2016;39:218-222.
99. Luen S, Salgado R, Fox SB, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncology. 2017;18:52-62.
100. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8:74-80.
101. Bienkowski M, Preusser M. Prognostic role of tumourinfiltrating inflammatory cells in brain tumours: literature review. Curr Opin Neurol. 2015;28:647-658.
102. Berghoff AS, Fuchs E, Ricken G, et al. Density of tumorinfiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016;5:e1057388.
103. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996;74:43-47.
104. The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681-1696.
105. Kakavand H, Vilain RE, Wilmott JS, et al. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol. 2015;28:1535-1544.
106. Bogunovic D, O'Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A. 2009;106:20429-20434.
107. Schweiger T, Berghoff AS, Glogner C, et al. Tumorinfiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clin Exp Metastasis. 2016;33:727-739.
108. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670-5677.
109. Kwak Y, Koh J, Kim D-W, et al. Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget. 2016;7:81778-81790.
110. West NR, Panet-Raymond V, Truong PT, et al. Intratumoral immune responses can distinguish new primary and true recurrence types of ipsilateral breast tumor recurrences (IBTR). Breast Cancer (Auckl). 2011;5:105-115.
111. Dieci MV, Giaratano T, Miglietta F, et al. Abstract P2-05-20: tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: prognostic value according to tumor phenotype. Cancer Res. 2016;77:P2-05-20.
112. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571.
113. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828-860.
114. Kilvaer TK, Paulsen EE, Khanehkenari MR, et al. The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. Br J Cancer. 2016;114:1145-1151.
115. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285-293.
116. Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168:487-502. e415.
117. Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2015;8:327ra326.
118. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PDL1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med. 2013;5:ra116.
119. Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48-61.
120. Rizvi N, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non- small cell lung cancer. Science. 2015;348:124-128.
121. Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016;4:959-967.
122. Spranger S, Luke JJ, Bao R, et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A. 2016;113:E7759-E7768.
123. Sweis RF, Spranger S, Bao R, et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 2016;4:563-568.
124. Danilova L, Wang H, Sunshine J, et al. Association of PD-1/ PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A. 2016;113:E7769-E7777.
125. Smid M, Rodriguez-Gonzalez FG, Sieuwerts AM, et al. Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun. 2016;7:12910.
126. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic betacatenin signalling prevents anti-tumour immunity. Nature. 2015;523:231-235.
127. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74-80.